From wk @ to wk @ , inhibition of radiographic progression was maintained for ustekinumab-treated patients , and progression was substantially reduced among initial placebo recipients who started ustekinumab at wk @ or wk @ ( wk @ - wk @ , total vdH-S score mean change : @ ) .